{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:57:40Z","timestamp":1792241860278,"version":"4.4.0"},"reference-count":79,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate symptoms and improve quality of life. However, challenges persist, such as adverse effects, treatment resistance, high costs, and variability in response among individuals. The future of psoriasis treatment shows promising emerging trends. New biologic agents targeting novel pathways, such as interleukin 23 inhibitors like mirikizumab, offer enhanced efficacy. Small molecule inhibitors like ROR\u03b3t inhibitors and ROCK2 inhibitors provide additional treatment options. Combination therapies, including biologics with methotrexate, may improve treatment response. Advancements in topical treatments utilizing microneedles and nanoparticle-based carriers can enhance drug delivery and improve therapeutic outcomes. Biomarkers and multi-omics technologies hold potential for personalized treatment approaches, thus aiding in diagnosis, predicting treatment response, and guiding therapeutic decisions. Collaboration among researchers, clinicians, and industry stakeholders is crucial to translating these scientific breakthroughs into clinical practice. By addressing current challenges and exploring these promising trends, we can optimize psoriasis management and improve the lives of those affected by this chronic condition.<\/jats:p>","DOI":"10.3390\/ijms241713313","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T03:45:42Z","timestamp":1693194342000},"page":"13313","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":290,"title":["Challenges and Future Trends in the Treatment of Psoriasis"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-8462","authenticated-orcid":false,"given":"Hyun-Ji","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Yeongdeungpo-gu, Seoul 07345, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Yeongdeungpo-gu, Seoul 07345, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"ref_1","unstructured":"World Health, O. (2016). Global Report on Psoriasis, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"adv00032","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and Treatment: Past, Present and Future Aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2174\/1389450122666210118103455","article-title":"Recent Advances in Psoriasis Therapy: Trends and Future Prospects","volume":"22","author":"Singh","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40257-022-00703-1","article-title":"Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review","volume":"23","author":"Alinaghi","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s13555-023-00903-5","article-title":"Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review","volume":"13","author":"Hsieh","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1080\/09546634.2021.1966357","article-title":"Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis","volume":"33","author":"Pourani","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjd.20517","article-title":"The promise and challenges of cell therapy for psoriasis","volume":"185","author":"Lwin","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Salgado-Boquete, L., Carrascosa, J.M., Llamas-Velasco, M., Ruiz-Villaverde, R., de la Cueva, P., and Belinch\u00f3n, I. (2021). A New Classification of the Severity of Psoriasis: What\u2019s Moderate Psoriasis?. Life, 11.","DOI":"10.3390\/life11070627"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0190-9622(97)70281-0","article-title":"Topical calcipotriol in childhood psoriasis","volume":"36","author":"Oranje","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000512930","article-title":"Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway","volume":"237","author":"Maul","year":"2021","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2018.03.040","article-title":"Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials","volume":"79","author":"Gold","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","first-page":"e15364","article-title":"Proactive therapy: New perspectives for long-term topical treatment of psoriasis","volume":"35","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/ijd.12790","article-title":"The role of vitamin D in psoriasis: A review","volume":"54","author":"Soleymani","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"adv00890","DOI":"10.2340\/actadv.v103.6525","article-title":"Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review","volume":"103","author":"Amiri","year":"2023","journal-title":"Acta Derm.-Venereol."},{"key":"ref_21","first-page":"35","article-title":"The 308\u2009nm Excimer laser for the treatment of psoriasis and inflammatory skin diseases","volume":"69","author":"Fritz","year":"2018","journal-title":"Der Hautarzt Z. Dermatol. Venerol. Verwandte Geb."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jdv.16684","article-title":"Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)","volume":"34","author":"Lambert","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2014.08.050","article-title":"OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results","volume":"72","author":"Kimball","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","article-title":"Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry","volume":"7","author":"Menter","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2310\/7750.2009.09007","article-title":"Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: Case report and literature review","volume":"14","author":"Poulin","year":"2010","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1586\/1744666X.2015.1095092","article-title":"Secukinumab (AIN457) for the treatment of psoriasis","volume":"11","author":"Vilarrasa","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"212570","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: Evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","article-title":"Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the Biobadaderm Registry","volume":"137","author":"Dauden","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14712598.2019.1579794","article-title":"Brodalumab for the treatment of plaque psoriasis: Up-to-date","volume":"19","author":"Beck","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/j.1468-3083.2012.04585.x","article-title":"Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis","volume":"27","author":"Puig","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_38","first-page":"Cd010227","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis","volume":"2016","author":"Hazlewood","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40257-014-0097-1","article-title":"Use of biologic agents in combination with other therapies for the treatment of psoriasis","volume":"15","author":"Cather","year":"2014","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2133.2010.09999.x","article-title":"Switching biologics for psoriasis","volume":"163","author":"Ormerod","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000504839","article-title":"Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience","volume":"237","author":"Aytekin","year":"2021","journal-title":"Dermatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/1346-8138.13860","article-title":"Switching of biologics in psoriasis: Reasons and results","volume":"44","author":"Honda","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","article-title":"Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States","volume":"34","author":"Armstrong","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/IJDVL_308_2022","article-title":"Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea","volume":"28","author":"Shin","year":"2023","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.36849\/JDD.6589","article-title":"Unmet Needs in Psoriasis Patients","volume":"21","author":"Porter","year":"2022","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/bcp.15101","article-title":"Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review","volume":"88","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.36849\/JDD.6498","article-title":"Treatment of Scalp Psoriasis","volume":"21","author":"Ghafoor","year":"2022","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ced.14314","article-title":"Management of nail psoriasis","volume":"46","author":"Thomas","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-019-00447-5","article-title":"Genital Psoriasis: Impact on Quality of Life and Treatment Options","volume":"20","author":"Kelly","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","article-title":"Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments","volume":"21","author":"Zozula","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/jdv.14949","article-title":"Generalized pustular psoriasis: A review and update on treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2013signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis\u2014A network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Madonna, S., Girolomoni, G., Dinarello, C.A., and Albanesi, C. (2019). The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133318"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small Molecule IL-36\u03b3 Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis","volume":"9","author":"Su","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/bjd\/ljac049","article-title":"Spesolimab in the treatment of generalized pustular psoriasis: A critically appraised research paper","volume":"188","author":"Ali","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Conti, P., Pregliasco, F.E., Bellomo, R.G., Gallenga, C.E., Caraffa, A., Kritas, S.K., Lauritano, D., and Ronconi, G. (2021). Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158076"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3389\/fimmu.2018.01210","article-title":"Transcription Factor Retinoid-Related Orphan Receptor \u03b3t: A Promising Target for the Treatment of Psoriasis","volume":"9","author":"Tang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating Autoimmune Diseases with Retinoic Acid Receptor-Related Orphan Receptor-\u03b3 (ROR\u03b3 or RORc) Inhibitors: Hits and Misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.4049\/jimmunol.1602142","article-title":"Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10","volume":"198","author":"Weiss","year":"2017","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1039\/D2TB00614F","article-title":"Latest on biomaterial-based therapies for topical treatment of psoriasis","volume":"10","author":"Chen","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.actbio.2020.12.004","article-title":"Microneedle-mediated transdermal drug delivery for treating diverse skin diseases","volume":"121","author":"Yang","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjd.15779","article-title":"A hyaluronic acid-based microneedle patch to treat psoriatic plaques: A pilot open trial","volume":"178","author":"Lee","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"43588","DOI":"10.1021\/acsami.9b15668","article-title":"Hyaluronic Acid-Based Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis","volume":"11","author":"Du","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eabe2888","DOI":"10.1126\/sciadv.abe2888","article-title":"Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders","volume":"7","author":"Wan","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2018.11.032","article-title":"Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases","volume":"555","author":"Carter","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2015.03.020","article-title":"Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study","volume":"485","author":"Abdelbary","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.colsurfb.2016.01.021","article-title":"Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis","volume":"141","author":"Bessar","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jid.2019.09.018","article-title":"Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis","volume":"140","author":"Sahin","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/exd.13707","article-title":"Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF-\u03baB activity","volume":"27","author":"Crisan","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gomez, C., Muangnoi, C., Sorasitthiyanukarn, F.N., Wongpiyabovorn, J., Rojsitthisak, P., and Rojsitthisak, P. (2019). Synergistic Effects of Photo-Irradiation and Curcumin-Chitosan\/Alginate Nanoparticles on Tumor Necrosis Factor-Alpha-Induced Psoriasis-Like Proliferation of Keratinocytes. Molecules, 24.","DOI":"10.3390\/molecules24071388"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3389\/fimmu.2020.01855","article-title":"Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis","volume":"11","author":"Shores","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s43094-021-00324-1","article-title":"Nanofiber as a novel vehicle for transdermal delivery of therapeutic agents: Challenges and opportunities","volume":"7","author":"Kumar","year":"2021","journal-title":"Future J. Pharm. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: A scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br. J. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13313\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:37Z","timestamp":1760128837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":79,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241713313"],"URL":"https:\/\/doi.org\/10.3390\/ijms241713313","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}